# A Study to Evaluate the Efficacy, Response Duration and Safety of Xolair (Omalizumab) in Patients With Chronic Idiopathic Urticaria (CIU)/Chronic Spontaneous Urticaria (CSU) Who Remain Symptomatic Despite Antihistamine Treatment (H1)

> **NCT01292473** · PHASE3 · COMPLETED · sponsor: **Genentech, Inc.** · enrollment: 323 (actual)

## Conditions studied

- Chronic Idiopathic Urticaria

## Interventions

- **DRUG:** Placebo
- **DRUG:** Omalizumab

## Key facts

- **NCT ID:** NCT01292473
- **Lead sponsor:** Genentech, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2011-03
- **Primary completion:** 2012-06
- **Final completion:** 2012-06
- **Target enrollment:** 323 (ACTUAL)
- **Last updated:** 2013-10-11


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01292473

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01292473, "A Study to Evaluate the Efficacy, Response Duration and Safety of Xolair (Omalizumab) in Patients With Chronic Idiopathic Urticaria (CIU)/Chronic Spontaneous Urticaria (CSU) Who Remain Symptomatic Despite Antihistamine Treatment (H1)". Retrieved via AI Analytics 2026-09-03 from https://api.ai-analytics.org/clinical/NCT01292473. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*